Introduction
cancers, toxicity, HRD, pancreatic cancer, tumors
CANCERS, TUMORS, PANCREATIC CANCER
Multiagent DNA-damaging chemotherapy has been a critical therapeutic tool to treat a wide variety of cancers for decades. With the development of novel targeted therapies, there have been attempts to evaluate rational combinations of targeted agents with chemotherapy. The goal of combination strategies is to enhance efficacy, without increasing the toxicity of the multiagent chemotherapies. Inhibitors of PARP are targeted agents that result in impairment of the base excision repair pathway and have monotherapy activity in tumors with homologous recombination deficiency (HRD) such as breast, ovarian, and pancreatic cancer (We and others have previously outlined the preclinical data, which demonstrates synergy between PARPis and topoisomerase I inhibitors, both The NCI 7977 trial was a multicohort phase I study evaluating different dosing schedules of veliparib in combination with irinotecan. We previously published the continuous veliparib dosing cohort which revealed a MTD of veliparib 40 mg twice daily administered on days -1 to 14 of a 21-day cycle with irinotecan 100 mg/m